| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 382.5 | 363.7 | 324.9 |
| Other income | 3.9 | 3.9 | 5.0 |
| Total income | 386.4 | 367.6 | 329.9 |
| Profit before exceptional items & tax | 150.1 | 97.3 | 119.0 |
| Exceptional items | 0.0 | 31.8 | 0.0 |
| Profit before tax | 150.1 | 129.1 | 119.0 |
| Net profit | 111.5 | 96.2 | 88.5 |
| Operating margin | 38.8% | 35.1% | 36.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +26.00% |
|---|---|
| Net profit, quarter on quarter | +15.90% |
| Revenue, year on year | +17.70% |
| Operating profit, year on year | +28.20% |
| Operating profit, quarter on quarter | +56.50% |
BSE results filing, NSE: PGHL. Figures extracted from the filing.
Procter & Gamble Health Ltd: key numbers
- Share price
- ₹5,670.50
- Market cap
- ₹9,413 Cr
- Revenue (annual)
- ₹1,408 Cr
- Net profit (annual)
- ₹326.9 Cr
- P/E (TTM)
- 26.4×Sector 45.9×
- Promoter holding
- 51.82%+0.00% QoQ
- FII holding
- 6.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Procter & Gamble Health Ltd
All →Procter & Gamble Health Results Update
P&G Health's Q2 sales grew 18% to ₹376 crore and PAT rose 26% to ₹112 crore. Growth driven by brand strength and retail execution.
Procter & Gamble Health Board Meeting Date
Procter & Gamble Health Limited will hold a board meeting on November 2, 2026, to consider and approve the unaudited financial results for the quarter ending September 30, 2026.
Procter & Gamble Health Other Announcement
Procter & Gamble Health informed shareholders about an extended SEBI-mandated special window for re-lodging rejected physical share transfer requests until February 4, 2027.
Procter & Gamble Health Management Change
Procter & Gamble Health shareholders approved the re-appointment of Mr. S. Madhavan as an Independent Director for a five-year term starting November 15, 2026.
- Execution
- 5 years
Procter & Gamble Health Annual General Meeting
Procter & Gamble Health held its 59th Annual General Meeting on September 3, 2026, where shareholders discussed financial results and directorial appointments.
Procter & Gamble Health Business Update
Procter & Gamble Health Limited has filed its Business Responsibility & Sustainability Report for the financial year ended March 31, 2026.